Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for Treatment Resistant Schizophrenia
NCT04887792Phase 2Recruiting
- Start
- Feb 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of acetazolamide in schizophrenia, schizoaffective disorder. Started Feb 2022; status: recruiting.
02
Drugs
acetazolamide
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT04887792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887792.